IBDEI2U8 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,47624,1,4,0)
 ;;=4^C91.31
 ;;^UTILITY(U,$J,358.3,47624,2)
 ;;=^5001769
 ;;^UTILITY(U,$J,358.3,47625,0)
 ;;=C91.32^^209^2346^448
 ;;^UTILITY(U,$J,358.3,47625,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47625,1,3,0)
 ;;=3^Prolymphocytic Leukemia of B-Cell Type,In Relapse
 ;;^UTILITY(U,$J,358.3,47625,1,4,0)
 ;;=4^C91.32
 ;;^UTILITY(U,$J,358.3,47625,2)
 ;;=^5001770
 ;;^UTILITY(U,$J,358.3,47626,0)
 ;;=C91.40^^209^2346^212
 ;;^UTILITY(U,$J,358.3,47626,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47626,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,47626,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,47626,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,47627,0)
 ;;=C91.41^^209^2346^211
 ;;^UTILITY(U,$J,358.3,47627,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47627,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,47627,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,47627,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,47628,0)
 ;;=C91.42^^209^2346^210
 ;;^UTILITY(U,$J,358.3,47628,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47628,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,47628,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,47628,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,47629,0)
 ;;=C91.50^^209^2346^36
 ;;^UTILITY(U,$J,358.3,47629,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47629,1,3,0)
 ;;=3^Adult T-Cell Lymphoma/Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,47629,1,4,0)
 ;;=4^C91.50
 ;;^UTILITY(U,$J,358.3,47629,2)
 ;;=^5001774
 ;;^UTILITY(U,$J,358.3,47630,0)
 ;;=C91.51^^209^2346^35
 ;;^UTILITY(U,$J,358.3,47630,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47630,1,3,0)
 ;;=3^Adult T-Cell Lymphoma/Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,47630,1,4,0)
 ;;=4^C91.51
 ;;^UTILITY(U,$J,358.3,47630,2)
 ;;=^5001775
 ;;^UTILITY(U,$J,358.3,47631,0)
 ;;=C91.52^^209^2346^34
 ;;^UTILITY(U,$J,358.3,47631,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47631,1,3,0)
 ;;=3^Adult T-Cell Lymphoma/Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,47631,1,4,0)
 ;;=4^C91.52
 ;;^UTILITY(U,$J,358.3,47631,2)
 ;;=^5001776
 ;;^UTILITY(U,$J,358.3,47632,0)
 ;;=C91.60^^209^2346^449
 ;;^UTILITY(U,$J,358.3,47632,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47632,1,3,0)
 ;;=3^Prolymphocytic Leukemia of T-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,47632,1,4,0)
 ;;=4^C91.60
 ;;^UTILITY(U,$J,358.3,47632,2)
 ;;=^5001777
 ;;^UTILITY(U,$J,358.3,47633,0)
 ;;=C91.61^^209^2346^450
 ;;^UTILITY(U,$J,358.3,47633,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47633,1,3,0)
 ;;=3^Prolymphocytic Leukemia of T-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,47633,1,4,0)
 ;;=4^C91.61
 ;;^UTILITY(U,$J,358.3,47633,2)
 ;;=^5001778
 ;;^UTILITY(U,$J,358.3,47634,0)
 ;;=C91.62^^209^2346^451
 ;;^UTILITY(U,$J,358.3,47634,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47634,1,3,0)
 ;;=3^Prolymphocytic Leukemia of T-Cell Type,In Relapse
 ;;^UTILITY(U,$J,358.3,47634,1,4,0)
 ;;=4^C91.62
 ;;^UTILITY(U,$J,358.3,47634,2)
 ;;=^5001779
 ;;^UTILITY(U,$J,358.3,47635,0)
 ;;=C91.A0^^209^2346^301
 ;;^UTILITY(U,$J,358.3,47635,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47635,1,3,0)
 ;;=3^Mature B-Cell Leukemia Burkitt Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,47635,1,4,0)
 ;;=4^C91.A0
 ;;^UTILITY(U,$J,358.3,47635,2)
 ;;=^5001783
 ;;^UTILITY(U,$J,358.3,47636,0)
 ;;=C91.A1^^209^2346^299
 ;;^UTILITY(U,$J,358.3,47636,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47636,1,3,0)
 ;;=3^Mature B-Cell Leukemia Burkitt Type,In Remission
 ;;^UTILITY(U,$J,358.3,47636,1,4,0)
 ;;=4^C91.A1
 ;;^UTILITY(U,$J,358.3,47636,2)
 ;;=^5001784
